Published in Front Endocrinol (Lausanne) on April 11, 2012
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid (2014) 0.91
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab (2013) 0.90
Novel approaches in anaplastic thyroid cancer therapy. Oncologist (2014) 0.86
The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) (2016) 0.85
Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget (2016) 0.82
Genetic and epigenetic alterations in differentiated thyroid carcinoma. J Med Life (2013) 0.81
Radiation signatures in childhood thyroid cancers after the Chernobyl accident: possible roles of radiation in carcinogenesis. Cancer Sci (2015) 0.81
Molecular pathways associated with aggressiveness of papillary thyroid cancer. Curr Genomics (2014) 0.79
Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations. PLoS One (2014) 0.79
Adult mitochondrial DNA depletion syndrome with mild manifestations. Neurol Int (2013) 0.77
miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. BMC Cancer (2016) 0.76
Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther (2015) 0.75
Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma. Expert Opin Ther Targets (2015) 0.75
Methylation of sodium iodide symporter promoter correlated with aggressiveness and metastasis in papillary thyroid carcinoma: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine. Eur Thyroid J (2017) 0.75
Hobnail Variant of Papillary Thyroid Carcinoma: a Literature Review. Endocr Pathol (2017) 0.75
N-Acetyl-L-cysteine protects thyroid cells against DNA damage induced by external and internal irradiation. Radiat Environ Biophys (2017) 0.75
Values of molecular markers in the differential diagnosis of thyroid abnormalities. J Cancer Res Clin Oncol (2016) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev (2009) 8.08
Management of a solitary thyroid nodule. N Engl J Med (1993) 7.15
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science (2000) 4.17
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol (1994) 3.78
Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res (1997) 3.06
Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot (2006) 3.03
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol (2009) 3.02
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
RET/PTC rearrangement in thyroid tumors. Endocr Pathol (2002) 2.42
Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res (1997) 2.35
Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ (2007) 2.28
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15
Cancer of the thyroid in children: a report of 28 cases. J Clin Endocrinol Metab (1950) 2.10
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res (1998) 2.00
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab (2006) 1.98
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene (1994) 1.87
Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev (2011) 1.86
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86
RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev (2005) 1.82
Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst (2009) 1.80
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Radiation mutagenesis: the initial DNA lesions responsible. Radiat Res (1995) 1.72
RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res (2008) 1.67
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab (2010) 1.63
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab (2009) 1.55
The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene (1990) 1.52
Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med (1992) 1.51
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab (2006) 1.39
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.38
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab (1999) 1.37
Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med (2011) 1.37
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer (2002) 1.32
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab (2001) 1.31
Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clin Endocrinol (Oxf) (2007) 1.30
High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene (1995) 1.29
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res (1998) 1.27
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer (2008) 1.26
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab (2005) 1.24
In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res (1993) 1.19
The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J Clin Endocrinol Metab (2000) 1.19
RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene (1995) 1.19
The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. Cancer (1987) 1.18
Radiation-induced thyroid cancer: what we have learned from chernobyl. Endocr Pathol (2006) 1.18
RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol (2001) 1.18
Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr Pract (2004) 1.14
BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol (2006) 1.12
Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab (2001) 1.11
RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol (2011) 1.10
DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene (2010) 1.09
Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene (1991) 1.06
Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.06
Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer (1999) 1.04
Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid (2004) 1.03
Cancer incidence in a cohort of infertile women. Am J Epidemiol (1987) 1.03
ret/PTC-1 Activation in Hashimoto Thyroiditis. Int J Surg Pathol (2000) 1.02
Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA (1994) 1.02
The epidemiology of thyroid carcinoma. Crit Rev Oncog (1993) 1.02
High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab (2011) 1.00
RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet (2000) 0.99
Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET/PTC rearrangements. Oncogene (2006) 0.99
The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med (1994) 0.98
Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J (2010) 0.98
Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene (2000) 0.98
Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings. Ann Intern Med (1984) 0.97
Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res (2010) 0.96
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid (2007) 0.95
Fine-needle aspiration of the thyroid: today and tomorrow. Best Pract Res Clin Endocrinol Metab (2008) 0.94
The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J Clin Endocrinol Metab (2002) 0.93
Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery (2000) 0.92
Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Lab Invest (2004) 0.91
Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br J Cancer (1993) 0.91
Ethnic patterns of thyroid cancer incidence in the United States, 1973-1981. Int J Cancer (1988) 0.91
Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging (2009) 0.91
Effect of a mandatory iodization program on thyroid gland volume based on individuals' age, gender, and preceding severity of dietary iodine deficiency: a prospective, population-based study. J Clin Endocrinol Metab (2007) 0.89
ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients. Endocr Relat Cancer (2005) 0.89
BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance. Acta Cytol (2011) 0.87
Twenty years' experience with post-Chernobyl thyroid cancer. Best Pract Res Clin Endocrinol Metab (2008) 0.87
Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur J Endocrinol (2003) 0.87
Oncogene profile of papillary thyroid carcinoma. Surgery (1999) 0.85
Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia. Cancer (1994) 0.85
RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH. Br J Cancer (2006) 0.84
Cancer of the thyroid in children. Proc Natl Cancer Conf (1970) 0.83
Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Hum Pathol (1998) 0.83
Medical effects of exposure of human beings to fallout radiation from a thermonuclear explosion. Stem Cells (1995) 0.81
RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur J Endocrinol (2001) 0.81
Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. Arch Pathol Lab Med (2004) 0.80
Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia. J Clin Endocrinol Metab (2000) 0.79
Enhanced sensitivity of the RET proto-oncogene to ionizing radiation in vitro. Cancer Res (2008) 0.79
RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology (2010) 0.79
Chromosomal rearrangements in post-Chernobyl papillary thyroid carcinomas: evaluation by spectral karyotyping and automated interphase FISH. J Biomed Biotechnol (2011) 0.79
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid (2014) 1.81
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res (2012) 1.80
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab (2010) 1.50
Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid (2012) 1.45
Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab (2004) 1.32
Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. Thyroid (2013) 1.27
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer (2008) 1.26
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.16
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. J Clin Endocrinol Metab (2009) 1.04
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol (2010) 1.04
Genome-wide association study on differentiated thyroid cancer. J Clin Endocrinol Metab (2013) 1.03
Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid (2012) 1.00
Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther (2012) 0.99
Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab (2012) 0.98
Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid (2007) 0.98
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol (2002) 0.95
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab (2013) 0.94
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. J Clin Endocrinol Metab (2008) 0.94
Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid (2007) 0.92
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab (2003) 0.92
A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid (2009) 0.91
Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab (2002) 0.90
Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol (2008) 0.89
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol (2013) 0.89
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma. Int J Cancer (2011) 0.87
Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein. Clin Endocrinol (Oxf) (2003) 0.87
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. J Clin Endocrinol Metab (2014) 0.86
Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer (2007) 0.85
Medullary and papillary tumors are frequently associated in the same thyroid gland without evidence of reciprocal influence in their biologic behavior. Thyroid (2004) 0.83
Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab (2005) 0.82
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. Eur J Endocrinol (2010) 0.82
Risk of differentiated thyroid carcinoma and polymorphisms within the susceptibility cancer region 8q24. Cancer Epidemiol Biomarkers Prev (2013) 0.82
Expression of cAMP response element-binding protein and sodium iodide symporter in benign non-functioning and malignant thyroid tumours. Eur J Endocrinol (2003) 0.81
Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int J Cancer (2002) 0.80
Acute exogenous TSH administration stimulates leptin secretion in vivo. Eur J Endocrinol (2010) 0.79
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. Int J Cancer (2013) 0.79
Simian virus 40-like sequences from early and late regions in human thyroid tumors of different histotypes. J Clin Endocrinol Metab (2003) 0.79
Anaplastic thyroid cancer therapy: dream or reality? Endocrine (2012) 0.77
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma. Mol Cell Endocrinol (2011) 0.77
Incidental versus clinically evident thyroid cancer: a 5-year follow-up study. Head Neck (2012) 0.77
Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity. Hum Pathol (2007) 0.76
Effects of radioiodine treatment for differentiated thyroid cancer on testis function. Clin Endocrinol (Oxf) (2014) 0.76
Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes. J Pediatr Surg (2010) 0.75
Surgical Management of Medullary thyroid carcinoma in pediatric age. Curr Pediatr Rev (2016) 0.75
Role of YAP-1 in Thyroid Tumor Progression and Outcome. Appl Immunohistochem Mol Morphol (2016) 0.75
FoxP3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment. Thyroid (2013) 0.75
Medullary thyroid carcinoma in children. Endocr Dev (2014) 0.75